Ultragenyx Pharmaceutical Inc. Insider Trading for March 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Ultragenyx Pharmaceutical Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Ultragenyx Pharmaceutical Inc. for March 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 09 2021 | RARE | Ultragenyx Pharmac ... | Huizenga Theodore Alan | SVP, Controller and ... | Sell | S | 120.69 | 3,000 | 362,070 | 13,544 | 16.5 K to 13.5 K (-18.13 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Kassberg Thomas Richard | CBO & EVP | Option Exercise | A | 142.47 | 11,000 | 1,567,170 | 11,000 | |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Kassberg Thomas Richard | CBO & EVP | Sell | S | 138.17 | 4,572 | 631,713 | 107,181 | 111.8 K to 107.2 K (-4.09 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Kassberg Thomas Richard | CBO & EVP | Grant | A | 0.00 | 4,636 | 0 | 111,614 | 107 K to 111.6 K (+4.33 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Kassberg Thomas Richard | CBO & EVP | Grant | A | 0.00 | 5,500 | 0 | 106,978 | 101.5 K to 107 K (+5.42 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Pinion John Richard | See Remarks | Option Exercise | A | 142.47 | 11,000 | 1,567,170 | 11,000 | |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Pinion John Richard | See Remarks | Sell | S | 138.17 | 6,198 | 856,378 | 50,237 | 56.4 K to 50.2 K (-10.98 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Pinion John Richard | See Remarks | Grant | A | 0.00 | 4,636 | 0 | 56,435 | 51.8 K to 56.4 K (+8.95 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Pinion John Richard | See Remarks | Grant | A | 0.00 | 5,500 | 0 | 51,799 | 46.3 K to 51.8 K (+11.88 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Parschauer Karah Herdman | EVP and General Cou ... | Option Exercise | A | 142.47 | 11,000 | 1,567,170 | 11,000 | |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Parschauer Karah Herdman | EVP and General Cou ... | Sell | S | 138.17 | 3,970 | 548,535 | 30,227 | 34.2 K to 30.2 K (-11.61 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Parschauer Karah Herdman | EVP and General Cou ... | Grant | A | 0.00 | 4,636 | 0 | 34,197 | 29.6 K to 34.2 K (+15.68 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Parschauer Karah Herdman | EVP and General Cou ... | Grant | A | 0.00 | 5,500 | 0 | 29,561 | 24.1 K to 29.6 K (+22.86 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Huizenga Theodore Alan | SVP, Controller and ... | Option Exercise | A | 142.47 | 4,655 | 663,198 | 4,655 | |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Huizenga Theodore Alan | SVP, Controller and ... | Sell | S | 138.17 | 732 | 101,140 | 16,544 | 17.3 K to 16.5 K (-4.24 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Huizenga Theodore Alan | SVP, Controller and ... | Grant | A | 0.00 | 1,560 | 0 | 17,276 | 15.7 K to 17.3 K (+9.93 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Option Exercise | A | 142.47 | 11,000 | 1,567,170 | 11,000 | |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Sell | S | 138.16 | 707 | 97,679 | 27,813 | 28.5 K to 27.8 K (-2.48 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Sell | S | 138.17 | 2,470 | 341,280 | 28,520 | 31 K to 28.5 K (-7.97 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Grant | A | 0.00 | 4,636 | 0 | 30,990 | 26.4 K to 31 K (+17.59 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Harris Erik | EVP & Chief Commerc ... | Grant | A | 0.00 | 5,500 | 0 | 26,354 | 20.9 K to 26.4 K (+26.37 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Huang Dennis Karl | EVP & Chief Tech Op ... | Option Exercise | A | 142.47 | 11,000 | 1,567,170 | 11,000 | |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Huang Dennis Karl | EVP & Chief Tech Op ... | Sell | S | 138.18 | 4,255 | 587,956 | 40,761 | 45 K to 40.8 K (-9.45 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Huang Dennis Karl | EVP & Chief Tech Op ... | Grant | A | 0.00 | 4,636 | 0 | 44,835 | 40.2 K to 44.8 K (+11.53 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Huang Dennis Karl | EVP & Chief Tech Op ... | Grant | A | 0.00 | 5,500 | 0 | 40,199 | 34.7 K to 40.2 K (+15.85 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Dier Mardi | CFO & Executive Vic ... | Option Exercise | A | 142.47 | 11,000 | 1,567,170 | 11,000 | |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Dier Mardi | CFO & Executive Vic ... | Grant | A | 0.00 | 5,500 | 0 | 45,500 | 40 K to 45.5 K (+13.75 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Bedrosian Camille L | EVP and Chief Medic ... | Option Exercise | A | 142.47 | 11,000 | 1,567,170 | 11,000 | |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Bedrosian Camille L | EVP and Chief Medic ... | Sell | S | 138.18 | 4,543 | 627,752 | 39,139 | 43.7 K to 39.1 K (-10.40 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Bedrosian Camille L | EVP and Chief Medic ... | Grant | A | 0.00 | 4,636 | 0 | 43,682 | 39 K to 43.7 K (+11.87 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | Bedrosian Camille L | EVP and Chief Medic ... | Grant | A | 0.00 | 5,500 | 0 | 39,046 | 33.5 K to 39 K (+16.40 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Option Exercise | A | 142.47 | 36,000 | 5,128,920 | 36,000 | |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Sell | S | 141.80 | 30,000 | 4,254,000 | 2,289,741 | 2.3 M to 2.3 M (-1.29 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Payment of Exercise | F | 142.47 | 16,342 | 2,328,245 | 596,052 | 612.4 K to 596.1 K (-2.67 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Grant | A | 0.00 | 15,453 | 0 | 612,394 | 596.9 K to 612.4 K (+2.59 %) |
| Mar 03 2021 | RARE | Ultragenyx Pharmac ... | KAKKIS EMIL D | President & CEO | Grant | A | 0.00 | 18,000 | 0 | 596,941 | 578.9 K to 596.9 K (+3.11 %) |